Core Insights - Quest Diagnostics Incorporated (DGX) is valued at $20.6 billion and provides diagnostic testing services both in the U.S. and internationally, including routine and advanced clinical testing [1] Financial Performance - Analysts expect DGX to report an adjusted profit of $2.51 per share for Q3, reflecting a 9.1% increase from $2.30 per share in the same quarter last year [2] - For the full fiscal year 2025, DGX is projected to achieve an adjusted EPS of $9.74, a 9.1% increase from $8.93 in 2024, with further growth expected in fiscal 2026 to $10.40 per share, representing a 6.8% year-over-year increase [3] Stock Performance - DGX stock has increased by 24.5% over the past 52 weeks, significantly outperforming the Healthcare Select Sector SPDR Fund's 7% decline and the S&P 500 Index's 13.4% gain during the same period [4] - Following the release of strong Q2 results, DGX stock rose by 7.1%, with net revenues for the quarter reaching $2.8 billion, a 15.2% year-over-year increase, surpassing expectations by 1.5% [5] Analyst Ratings - The consensus rating for DGX is "Moderate Buy," with 8 out of 18 analysts recommending "Strong Buys" and 10 suggesting "Holds," while the stock is trading slightly below the mean price target of $189.94 [6]

Core Insights - Quest Diagnostics and Epic have announced a collaboration aimed at enhancing the laboratory testing experience for healthcare providers and patients in the United States [1][2][3] Group 1: Collaboration Details - The partnership will support Project Nova, a multi-year initiative by Quest to simplify and improve customer-facing processes, enhancing experiences for patients and providers across various EHR platforms [2][5] - Epic's Diagnostic Enterprise system will be integrated into Quest's national laboratory operations, including technologies like Aura, Beaker Laboratory, and MyChart [2][3] Group 2: Expected Benefits - Customers can expect faster and more convenient services, improved access to health insights, and quicker turnaround times for testing services [4][7] - The collaboration aims to streamline systems related to lab ordering, results reporting, and patient appointment scheduling, enhancing overall operational efficiency [7] Group 3: Leadership and Implementation - A cross-organization team experienced in large-scale implementations will oversee a phased rollout, ensuring a smooth transition for health systems and providers [5] - The focus will be on creating a comprehensive test list and improving patient engagement through MyChart [3][5]